A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Status:
RECRUITING
Trial end date:
2027-01-29
Target enrollment:
Participant gender:
Summary
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.